“…Additionally, while explaining the role of FAK in signaling pathways and tumor development, we found promising therapeutic targets that can be synergistically combined with FAK. Specifically, significant synergies were noted when FAK inhibitors were combined with mTOR inhibitors (Shi et al, 2016;Cuellar-Vite et al, 2022), RAF/ MEK inhibitors (Capelletto et al, 2022;Gu et al, 2022;Tarin et al, 2023), CDK4/6 inhibitors (Murphy et al, 2022;Peng et al, 2023), MAPK inhibitors (Peng et al, 2023), and VEGF inhibitors such as bevacizumab (Zheng et al, 2023). Furthermore, we observed an upregulation of FAK in specific tumor types with gene mutations or aberrant protein expression, such as BRAF/KRAS mutations, CDH1 deletions, EGFR or HER2 overexpression, and mediated drug resistance processes (Tong et al, 2019;Yuen et al, 2021;Yu et al, 2022;Castro-Guijarro et al, 2023).…”